Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

The Covid-19 virus is being called a black swan event. I’m not sure it meets all the criteria. After all, this isn’t the first virus from China that the world has had to confront. But it is a ...

CoDiagnostics, Inc. (CODX Quick Quote CODX - Free Report) shares ended the last trading session 9.7% higher at $8.62. The jump came on an impressive volume with a higher-than-average number of shares ...

Specializing in molecular diagnostic polymerase chain reaction (PCR) tests, Co-Diagnostics (NASDAQ:CODX) represents an extremely relevant business in the new normal. Early this morning, the company ...

Investors might want to bet on Co-Diagnostics, Inc. (CODX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

CODX received its first issued patent for the Co-Dx PCR platform from the Australian Patent Office. CODX's patent covers the PCR Pro instrument and proprietary test cups for point-of-care use. CODX is ...

The molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is CoDiagnostics, Inc. (CODX) one of those stocks right now? A ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Co-Diagnostics (CODX) is a stock that can certainly grab the attention of many ...

) has been revised to $2.04 / share. This is a decrease of 63.64% from the prior estimate of $5.61 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...